Clinical AdvisorAdverse Effect From Antipsychotic Leads to Lack of Informed Consent Claim

⚖️ Legal / Ethical Complexity
A Rhode Island court ruled that prior consent to one antipsychotic does not extend to another in the same class, even when both carry shared risks. The case proceeds to trial after a patient developed permanent tardive dyskinesia following a switch from quetiapine to ziprasidone.

Professional Impact

• Court held that knowing the risks of one drug does not imply knowledge of risks for another agent in the same therapeutic class, including risk magnitude.
• Documentation gaps were central: the NP’s records did not reflect any discussion of ziprasidone-specific adverse effects or alternatives at the time of prescribing.
• Ruling reinforces that each new prescription triggers a fresh informed consent obligation, not a carryover from prior class exposure.
• Rhode Island applies a subjective patient standard rather than the reasonable-person standard used in many states, raising the documentation bar for prescribers practicing there.

Action Items

• Document a fresh risk-benefit discussion for every new prescription, even within the same class.
• Establish standardized consent workflows that capture drug-specific adverse effects and alternatives.
• Review prescribing notes to confirm tardive dyskinesia and movement disorder risks are explicitly addressed for all antipsychotics.
• Train clinical staff on jurisdiction-specific informed consent standards, including subjective versus reasonable-person frameworks.